Table 10—

Reduction in 10-year risk of major CVD end points (CHD death/non-fatal MI) in major statin trials, or substudies of major trials, in diabetic subjects (n = 16,032)

Study (ref.)CVD preventionStatin dose and comparatorRisk reduction (%)Relative risk reduction (%)Absolute risk reduction (%)LDL cholesterol reduction
4S-DM (186)Simvastatin 20–40 mg vs. placebo85.7 to 43.25042.5186 to 119 mg/dl (36%)
ASPEN 2° (191)Atorvastatin 10 mg vs. placebo39.5 to 24.53412.7112 to 79 mg/dl (29%)
HPS-DM (187)Simvastatin 40 mg vs. placebo43.8 to 36.3177.5123 to 84 mg/dl (31%)
CARE-DM (188)Pravastatin 40 mg vs. placebo40.8 to 35.4135.4136 to 99 mg/dl (27%)
TNT-DM (189)Atorvastatin 80 mg vs. 10 mg26.3 to 21.6184.799 to 77 mg/dl (22%)
HPS-DM (187)Simvastatin 40 mg vs. placebo17.5 to 11.5346.0124 to 86 mg/dl (31%)
CARDS (209)Atorvastatin 10 mg vs. placebo11.5 to 7.5354118 to 71 mg/dl (40%)
ASPEN (191)Atorvastatin 10 mg vs. placebo9.8 to 7.9191.9114 to 80 mg/dl (30%)
ASCOT-DM (190)Atorvastatin 10 mg vs. placebo11.1 to 10.280.9125 to 82 mg/dl (34%)
  • Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation, results of the statin on 10-year risk of major CVD end points (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, Pharm.D., Oregon Health & Science University, 2007.